Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 12, 2013, Pages

  Fahimi, Fanak ^a,b   Tabarsi, Payam ^c   Kobarfard, F ^b   Bozorg, B D ^b   Goodarzi, A ^b   Dastan, F ^b   Shahsavari, N ^b   Emami, S ^a   Habibi, M ^a   Salamzadeh, J ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Plasma concentrations; Therapeutic drug monitoring

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REFERENCE VALUE;

ADULT; AGED; ANTITUBERCULAR AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IRAN; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; REFERENCE STANDARDS; REFERENCE VALUES; RIFAMPIN; TERTIARY CARE CENTERS; TREATMENT FAILURE; TUBERCULOSIS, PULMONARY;

EID: 84888083285     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0019     Document Type: Article

References (28)

1. Khazai H A, Rezaei N, Bagheri G R. Epidemiology of tuberculosis in the southeastern Iran. Eur J Epidemiol 2005; 20: 879-883. (Pubitemid 41618753)
2. World Health Organization. Tuberculosis. Fact Sheet no. 104. Geneva, Switzerland: WHO, 2012. http://www.who.int/mediacentre/factsheets/fs104/en/ Accessed September 2013.
3. Safdari H, Sadeghi A, Ghazvini K, Mohammadi S, Derakhshan M. Prevalence of Mycobacterium tuberculosis in the samples referred to the tuberculosis research laboratory in Mashhad Ghaem Hospital during 2005-2006. Iran J Microbiol 2009; 1: 20-22.
4. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for anti-tuberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
5. Peloquin C A. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-2183. (Pubitemid 35252827)
6. Laux G, Baumann P, Hiemke C, TDM group of the Arbeitsgemeinschaft Neuropsychopharmacologie und Pharmacopsychiatrie. Therapeutic drug monitoring of antidepressants-clinical aspects. J Neural Transm 2007; 72 (Suppl): 261-267.
7. Um S-W, Lee S W, Kwon S Y, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007; 11: 972-978. (Pubitemid 47425023)
8. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentration and outcome of tuberculosis treatment with onceweekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341-1347. (Pubitemid 36609717)
9. Peloquin C A, Benator D, Hayden K, et al. Low rifapentine, rifampin, and isoniazid plasma levels are not predicted by clinical and demographic features. Proceedings of the 97th American Lung Association/American Thoracic Society International Conference, 18-23 May 2001, San Francisco, CA, USA. Am J Respir Crit Care Med 2001; 163: A-498. [Abstract]
10. Kimerling M E, Phillips P, Patterson P, Hall M, Robinson C A, Dunlap N E. Low serum antimycobacterial drug levels in non- HIV-infected tuberculosis patients. Chest 1998; 113: 1178-1183. (Pubitemid 28223801)
11. Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 2011; 18: 225-229.
12. McIlleron H, Wash P, Burger A, Norman J, Folb P I, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50: 1170-1177.
13. Jiang Z, Wang H, Locke D C. Determination of ethambutol by ion-pair reversed phase liquid chromatography with UV detection. Analytica Chimica Acta 2002; 456: 189-192. (Pubitemid 34241434)
14. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 1996; 15: 394-405.
15. Heysell S K, Moore J L, Keller S J, Houpt E R. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16: 1546-1553.
16. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004; 38: 44- 48.
17. Holland D P, Hamilton C D, Weintrob A C, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 2009; 29: 503-510.
18. Tappero J W, Bradford W Z, Agerton T B, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 2005; 41: 461-469. (Pubitemid 41099637)
19. Ray J, Gardiner I, Marriott D. Managing anti-tuberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003; 33: 229-234. (Pubitemid 36718380)
20. Kayhan S, Akgüneş A. Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations. African J Pharm Pharmacol 2011; 5: 2035-2041.
21. Fahimi F, Kobarfard F, Tabarsi P, Hemmati S, Salamzadeh J, Baniasadi S. Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center. Chemotherapy 2011; 57: 7-11.
22. Roy P D, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 2008; 9: 311-321. (Pubitemid 351803934)
23. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
24. Bakayev V V, Mohammadi F, Bahadori M, et al. Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol 2004; 60: 467-471. (Pubitemid 39350159)
25. Peloquin C A. Use of therapeutic drug monitoring in tuberculosis patients. Chest 2004; 126: 1722-1724.
26. Khalili H, Fouladdel S, Sistanizad M, Hajiabdolbaghi M, Azizi E. Association of N -acetyltransferase-2 genotypes and antituberculosis induced liver injury; first case-controlled study from Iran. Curr Drug Saf 2011; 6: 17-22.
27. Singh S, Mariappan T T, Sharda N, Singh B. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions. Pharm Pharmacol Commun 2000; 6: 491-494.
28. Le Guellec C, Gaudet M L, Lamanetre S, Breteau M. Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies. Ther Drug Monit 1997; 19: 669-674. (Pubitemid 28046994)